What actually separates ACI from MACI

Despite appearing in patient searches as though one is simpler or quicker than the other, ACI and MACI are both two-stage procedures — and that is the first misconception worth clearing up before anything else.

The underlying biological principle is identical: cartilage cells (chondrocytes) are taken from your own knee during a short arthroscopic procedure, grown in a specialist laboratory over four to six weeks, and then returned to the damaged area through a second, small operation. What differs between the two approaches is how those cells are delivered at Stage 2.

In traditional ACI, the cultured cells arrive as a liquid suspension. The surgeon injects them directly into the defect and holds them in place by suturing a separate patch — periosteal tissue or a collagen membrane — over the top. In MACI, the cells are seeded uniformly onto a porcine Type I/III collagen membrane during the lab stage itself, so the implant arrives at surgery as a ready-made patch. The surgeon simply cuts it to the exact shape of the defect and fixes it with fibrin glue, with no sutures required.

MACI is formally classified as third-generation ACI — an evolution in delivery mechanics rather than a different treatment concept. Both procedures are indicated for focal, full-thickness chondral defects graded ICRS III or IV, broadly within the 2–10 cm² size range, and neither is appropriate where cartilage loss is diffuse throughout the joint.

How each operation is carried out

Stage 1 — the biopsy (identical for both)

The first operation is the same whichever implant follows. Under a general or spinal anaesthetic, the surgeon makes two or three small keyhole incisions around the knee and uses an arthroscope to take a small cartilage sample — typically from an area of the joint that bears little or no load. The procedure usually takes less than an hour, and most patients go home the same day.

The laboratory interval

The biopsy sample is sent to a specialist cell-culture facility, where chondrocytes are isolated and multiplied over approximately four to six weeks. At this stage the two techniques diverge: for ACI, the cells are expanded in suspension and returned as a liquid; for MACI, the laboratory seeds the cultured cells uniformly onto a porcine Type I/III collagen membrane, so the implant arrives at the second operation as a ready-made, cell-loaded patch.

Stage 2 — implantation

Both second operations use a small open incision — roughly two inches — rather than keyhole access. In ACI, the surgeon injects the liquid cell suspension into the prepared defect, then sutures a separate membrane over the top to contain the cells. In MACI, the pre-seeded scaffold is simply trimmed to match the defect outline and pressed into place with fibrin glue — a biological sealant derived from blood-clotting proteins — with no sutures needed to secure it. Eliminating suture fixation reduces mechanical stress on the surrounding healthy cartilage and lowers the risk of the patch lifting away or producing excess scar tissue (graft hypertrophy) during healing.

Which patients are suited to each technique

Selecting between ACI and MACI begins with a shared set of qualifying criteria, then narrows according to defect characteristics, surgical history, and anatomical detail.

The shared baseline

Both techniques are appropriate for focal, full-thickness chondral defects — typically graded ICRS III or IV — that fall within the approximate 2–10 cm² range in a skeletally mature patient with no evidence of diffuse osteoarthritis across the joint. Defects smaller than roughly 2 cm² are generally addressed with shorter single-stage procedures; larger defects may call for osteochondral allograft rather than a cell-based implant.

Where ACI may be the stronger fit

ACI carries the longer longitudinal evidence record and is associated with reported success rates of around 92% for isolated lesions and approximately 85% where multiple lesions are present in the same knee — a scenario that arises more often than patients might expect. For complex presentations involving more than one defect site, some consultants favour ACI's established track record.

One meaningful history factor: prior marrow-stimulation procedures such as microfracture are associated with higher failure rates for ACI. If microfracture has already been attempted, this needs to be discussed at assessment.

Where MACI tends to be preferred

For defects at or above 3 cm², MACI has solid mid-term randomised trial support — the SUMMIT Phase 3 trial is the most cited reference point, though its implications for the direct ACI–MACI comparison are discussed in the next section. The fibrin-glue fixation also suits certain anatomical locations, including the patella and trochlea, where suture-based fixation is more technically demanding.

Subchondral bone involvement is a relative contraindication for standard MACI, which is designed for lesions with an intact or near-intact bone base. Defects with meaningful osteochondral depth may need staged bone grafting or osteochondral allograft before or instead of a cell-based implant.

The honest variable: surgeon experience

In current practice, the choice between ACI and MACI is often shaped by a consultant's individual experience and local laboratory access as much as by defect characteristics alone. Asking directly about a surgeon's volume with each technique is a reasonable and worthwhile question to raise at consultation.

What the evidence shows about outcomes

Three trials shape most of what is currently known about outcomes — and reading them carefully matters, because the most prominent one is often misquoted.

The SUMMIT trial

The SUMMIT Phase 3 RCT is the most cited evidence for modern MACI. It showed MACI produced superior KOOS pain and function scores compared with microfracture at both two and five years for cartilage defects of 3 cm² or larger — the longest published follow-up for this comparison. That is a meaningful result, but the comparator was microfracture, not ACI. SUMMIT does not establish that MACI outperforms first-generation ACI; the two techniques were not tested against each other in this trial, and drawing that inference from its data would overstate what was shown.

The ACI–MACI head-to-head

The closest direct comparison remains a 2005 Bone and Joint Journal RCT in which clinical, arthroscopic, and histological outcomes were broadly equivalent for traditional ACI and MACI. Where MACI performed better, the advantage was procedural — lower rates of graft hypertrophy and fewer complications associated with suture fixation — rather than evidence of superior cartilage regeneration quality. Evidence beyond five years for this specific ACI-versus-MACI comparison is currently limited; the 2005 study remains the primary reference point for clinicians asking which technique produces better tissue over the long term. One clear acknowledgement of that data gap is more useful than repeated hedging throughout.

What both approaches share

Both cell-based techniques aim to restore hyaline-like cartilage — the smooth, load-bearing tissue that originally lined the joint — rather than the fibrocartilage produced by microfracture, which some studies suggest loses structural integrity within two to three years and may compromise the subchondral bone plate in a way that limits future repair options. That distinction partly explains the continued relevance of cell-based repair for larger focal defects.

Practical factors: cost, access, and recovery

Choosing between ACI and MACI is not purely a clinical decision — availability, cost, and the practical demands of a two-stage pathway shape what is actually achievable for any given patient.

Resource intensity and availability

Both procedures depend on specialist laboratory infrastructure to culture, quality-assure, and return the cell product to the operating surgeon. MACI's additional scaffold manufacturing step makes it more resource-intensive than earlier ACI generations, and outside major orthopaedic centres it is not uniformly available across all health systems. Neither procedure sits within the routine NHS tariff, so patients considering the private route should discuss fees directly at assessment rather than comparing figures in the abstract.

Two operations, two recovery periods

The two-stage structure means two separate anaesthetics and two distinct recovery windows to plan around. For most otherwise healthy patients this is manageable, but those with significant comorbidities — or limited practical capacity for staged procedures — may be better suited to a single-stage alternative, which is a question worth raising explicitly at consultation.

Post-operative rehabilitation follows a broadly similar trajectory for both techniques: protected weight-bearing for several weeks after implantation, with full return to sport generally expected somewhere in the 12–18 month range. That window is a planning reality, not a minor inconvenience, and it should be factored in before committing to either procedure.

Patients who want to be assessed without a GP referral or NHS waiting-list delay can access a consultant-led pathway through MSK Doctors.

Single-stage alternatives and where the field is heading

Yes, single-stage autologous chondrocyte approaches exist — and the question deserves a direct answer.

The most developed is single-treatment ACI (STACi), sometimes called next-generation ACI, which aims to collapse both operative stages into one session: cartilage is harvested, processed, and reimplanted without an intervening laboratory culture interval. Taylor and Lee (2019) provide the primary published framework for this approach. The important qualification is that STACi's evidence base remains substantially thinner than the decades of data behind established ACI and MACI — early promise and long-term comparative trial data are different things, and patients encountering STACi online should treat it as an emerging option rather than an established equivalent.

Other single-stage alternatives address different clinical situations. AMIC (autologous matrix-induced chondrogenesis) augments microfracture with a collagen scaffold but operates at the marrow-stimulation end of the spectrum and is not a cell-based procedure. Minced cartilage implantation shortens the operative timeline differently but targets a different defect profile. Neither is a direct substitute for ACI or MACI in the 2–10 cm² focal-defect range where those cell-based techniques carry the strongest supporting evidence.

The field is moving towards reducing operative burden where biology and evidence allow — that trajectory is real. What it does not yet mean is that single-stage options are interchangeable with established cell-based repair for every patient. Defect size, location, and prior surgical history all shape which generation of procedure offers the most reliable outcome, and that judgement is best made by a consultant who works across the full cartilage repair spectrum rather than within a single technique.

1. [1] Autologous chondrocyte implantation – Wikipedia. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150